I recently shared a new breakthrough on Modified Citrus Pectin (MCP) and the role of galectin-3 in health and disease in a poster presentation at the 8th International Conference of the Society for Integrative Oncology. The conference, held in Columbus, Ohio, brought together hundreds of top clinicians, researchers, patients and advocates to learn about new findings from different disciplines that have the potential to transform the treatment of cancer. The theme of this year’s meeting is “pinapabago Integrative Oncology: New Science, New Solutions. Focus patients “more than 80 abstracts will be presented, including my research on MCP and Galectin-3.
In the last decade, a large body of peer-reviewed research has revealed that many serious health problems associated with high levels of galectin-3 molecules. Modified Citrus Pectin – derived from citrus peels – is the only natural galectin-3 inhibitor proven to treat high galectin-3 for cancer, metastasis and other chronic diseases. During my poster presentation, I had the opportunity to discuss the latest research on Galectin-3, a new FDA-galectin-3 levels, and modified citrus pectin (MCP) approved. This conference gave me the opportunity to discuss new research on the people most likely to share their medical colleagues, patients and students. I hope that the peer-reviewed research presented has raised awareness of galectin-3 and modified citrus pectin on the importance of integrative oncology.
New discoveries offer new hope
Modified greater potential in the prevention and treatment of many serious health conditions that currently exist limited or no treatments available results provide new citrus pectin. As more research continues on the role of galectin-3 in various diseases, the usefulness ofModified Citrus Pectin will continue to grow as well, offering new hope patients seeking effective and safe therapy for fighting disease and restoring health naturally. Poster presentations of research topics:
Galectin-3 function in cancer cell proliferation, metastasis, inflammation and fibrosis
Galectin-3 and all death
Increased galectin-3 as a biomarker of disease
Modified Citrus Pectin as a Galectin-3 blocker
Modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and Independent Prostate Cancer Cell. Yan & Katz Columbia University
Modified Citrus Pectin Reduces Galectin-3 Expression and Disease Severity of experimental acute kidney injury. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Nephro-Urology Unit, UCL Institute of Child Health, London, UK
Research studies on the risk of death with higher serum galectin-3 levels
The importance of an integrative approach
As a holistic physician focused on treating cancer and chronic diseases that have been using MCP in my clinical practice for over 15 years. Because Modified Citrus Pectin safely and efficiently addresses so many serious health problems, is a perfect tool in integrative medicine. This is particularly true for the inclusion cancer therapy, where the disease must be attacked simultaneously from multiple angles. By blocking the effects of galectin-3 promotes cancer, reducing inflammation, chelating heavy metals, and providing powerful selective immune benefits including active NK cell induction, MCP is quickly becoming known as one of the nutrients more important in the fight against cancer and other serious health conditions.
I am very glad that my presentation enthusiastically received by doctors, researchers and other health professionals around the world. Great interest generated by this breakthrough research suggests that the need for successful solutions based integrative health science throughout the world. For more information on modified citrus pectin, download health guide